RxDoctor Payments Data

Paula Bryant, PA

Physician Assistant · West Jordan, UTNPI 1730429374

Payments from drug & device makers

$3,245in general payments, 2019–2025

Across 155 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$831
  • AstraZeneca$582
  • Abbott$566
  • AbbVie$262
  • BETA Bionics, Inc.$173
  • Novo Nordisk$142
  • plus $688 from 17 others

What the payments were for

  • Consulting fees$80025%
  • Food & beverage$2,44575%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,245 in reported general payments places this provider in the 90th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$19,638
Medicare patients
59
Services billed
368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide163$210,044
JardianceEmpagliflozin135$201,843
OzempicSemaglutide81$89,239
TrulicityDulaglutide60$63,914
FarxigaDapagliflozin Propanediol49$56,327
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$31,105
Lantus SolostarInsulin Glargine,hum.Rec.Anlog130$30,049
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/721$19,327
Novolog FlexpenInsulin Aspart50$15,595
Insulin Lispro Kwikpen U-100Insulin Lispro28$12,278
Humalog Kwikpen U-100Insulin Lispro28$10,133
VascepaIcosapent Ethyl15$9,322
Insulin Aspart FlexpenInsulin Aspart20$7,180
HumalogInsulin Lispro23$6,099
Icosapent Ethyl11$4,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$78$281,909262 claims
Boehringer IngelheimJardiance$44$201,843135 claims
Novo NordiskOzempic$142$89,23981 claims
AstraZenecaFarxiga$582$56,32749 claims
Sanofi-aventis U.S. LLCLantus$22$3,65324 claims
AbbVieSynthroid$262$24211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in West Jordan

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →